The first results of genetic screening and exploration of genotype-phenotype correlations in retinoblastoma patients from Belarus
- Authors: Guryanova I.E.1, Liubushkin A.V.1, Makarevich O.O.1, Litvinova D.Y.2, Vertеlko V.R.1, Valochnik A.V.1, Polyakova E.A.1, Migas A.A.1, Konoplya N.E.3
-
Affiliations:
- Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
- Belarusian State University
- N. N. Alexandrov National Cancer Centre
- Issue: Vol 21, No 2 (2022)
- Pages: 78-88
- Section: ORIGINAL ARTICLES
- Submitted: 24.06.2022
- Accepted: 24.06.2022
- Published: 08.07.2025
- URL: https://hemoncim.com/jour/article/view/619
- DOI: https://doi.org/10.24287/1726-1708-2022-21-2-78-88
- ID: 619
Cite item
Full Text
Abstract
Retinoblastoma is an aggressive eye tumor originating from maturing cone precursors in the developing retina and most commonly seen in childhood. In 98 % of patients, retinoblastoma is caused by bi-allelic inactivation of the RB1 tumor suppressor gene. Approximately 40 % of disorders in the RB1 gene are germline.
This study aimed to analyze the frequency of germline RB1 variants in a cohort of Belarusian patients with retinoblastoma and to correlate the variants with clinical phenotypes. The study was approved by an Independent Ethics Committee and the Scientific Council of the Belarusian Research Center for Pediatric Oncology, Hematology and Immunology. The study included 20 patients from unrelated families (9 patients with unilateral retinoblastoma, 11 – with bilateral). Two out of eleven patients with bilateral retinoblastoma had a positive family history. Genomic DNA was extracted from peripheral blood mononuclear cells. Using polymerase chain reaction, we obtained fragments including sequences of all exons, regions of splice sites and promoter regions of the RB1 gene. Nucleotide sequences of the obtained amplicons were detected by next-generation sequencing. All clinically significant variants were confirmed by Sanger sequencing. Multiplex ligation-dependent probe amplification (MLPA) or fluorescence in situ hybridization (FISH) were used to detect gross alterations. A genetic analysis of blood relatives was carried out for five probands with detected germline variants. We identified 13 different variants in 14 patients: 38.5 % (n = 5) of them were defects in splice sites; 15.4 % (n = 2) – missense mutations; 15.4 % (n = 2) – small deletions (frameshift); 23% (n = 3) – large deletions; 7.7% (n = 1) – nonsense mutations. Four of these variants had not been previously reported in patients with retinoblastoma from other populations (exon 3: c.350_351delTT, p. Phe117TyrfsTer2; exon 8: c.861+2T>G; exon 24: c.2520+4A>G; Del of exons 16, 17). Germline mutations were detected in 33.3 % (3/9) of patients with unilateral retinoblastoma and in 100% (11/11) of patients with bilateral disease. A genetic screening of relatives showed that three variants were de novo, and two variants were inherited from parents in families with a positive history of retinoblastoma. Here we reported the first results of genetic examination of Belarusian patients with retinoblastoma. Seventy-eight point six per cent (78.6 %) of variants were detected by sequencing, 21.4 % were identified with the help of the MLPA and FISH methods. Among sporadic cases, germline RB1 variants were detected in 66.6 % (12/18) of cases. A full range of screening techniques is required to achieve high sensitivity of detection in retinoblastoma patients. Our study also provides new evidence that will inform patient management and genetic counseling.
About the authors
I. E. Guryanova
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Author for correspondence.
Email: guryanovairina85@gmail.com
ORCID iD: 0000-0002-9696-3949
Irina E. Guryanova, senior researcher
Laboratory of Molecular Genetic Research
223053
43 Frunzenskaya St.
Minsk District
Borovlyany
Minsk
BelarusA. V. Liubushkin
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Minsk
BelarusO. O. Makarevich
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
ORCID iD: 0000-0001-8402-324X
Minsk
BelarusD. Yu. Litvinova
Belarusian State University
Minsk
BelarusV. R. Vertеlko
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Minsk
BelarusA. V. Valochnik
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
ORCID iD: 0000-0003-2474-0575
Minsk
BelarusE. A. Polyakova
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
ORCID iD: 0000-0002-0706-6622
Minsk
BelarusA. A. Migas
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Minsk
BelarusN. E. Konoplya
N. N. Alexandrov National Cancer Centre
ORCID iD: 0000-0003-0592-7182
Minsk
BelarusReferences
Supplementary files
